Skip to Main Content

Selected Publications

Akin EJ, Higerd GP, Mis MA, Tanaka BS, Adi T, Liu S, Dib-Hajj FB, Waxman SG, Dib-Hajj SD.Building sensory axons: Delivery and distribution of NaV1.7 channels and effects of inflammatory mediators. Sci Adv. 2019 Oct 23;5(10):eaax4755. doi: 10.1126/sciadv.aax4755. eCollection 2019 Oct.

Mis MA, Yang Y, Tanaka BS, Gomis-Perez C, Liu S, Dib-Hajj F, Adi T,Garcia-Milian R, Schulman BR, Dib-Hajj SD, Waxman SG. Resilience to Pain: A Peripheral Component Identified using induced Pluripotent Stem Cells and Dynamic Clamp. J Neurosci. 2018 Nov 20. pii: 2433-18.

Han C, Themistocleous AC, Estacion M, Dib-Hajj FB, Blesneac I, Macala L Fratter C, Bennett DL, Waxman SG, Dib-Hajj SD. The Novel Activity of Carbamazepine as an Activation Modulator Extends from Na(V)1.7 Mutations to the Na(V)1.8-S242T Mutant Channel from a Patient with Painful Diabetic Neuropathy. Mol Pharmacol. 2018 Nov;94(5):1256.

Yang Y, Mis MA, Estacion M, Dib-Hajj SD, Waxman SG. Na(V)1.7 as a Pharmacogenomic Target for Pain: Moving Toward Precision Medicine. Trends Pharmacol Sci. 2018 Mar;39(3):258.

Yang Y, Adi T, Effraim PR, Chen L, Dib-Hajj SD, Waxman SG. Reverse pharmacogenomics: carbamazepine normalizes activation and attenuates thermal hyperexcitability of sensory neurons due to Na(v) 1.7 mutation I234T. Br J Pharmacol. 2018 Jun;175(12):2261-2271.

Lankford KL, Arroyo EJ, Nazimek K, Bryniarski K, Askenase PW, Kocsis JD. Intravenously delivered mesenchymal stem cell-derived exosomes target M2-type macrophages in the injured spinal cord. PLoS One. 2018 Jan 2;13(1):e0190358.

Zakrzewska JM et al., Safety and efficacy of a Nav1.7 selective sodium channel blocker in patients with trigeminal neuralgia: a double-blind, placebo-controlled, randomised withdrawal phase 2a trial. Lancet Neurol. 2017 Feb 16. pii: S1474-4422(17)30005-4.

Geha P, Yang Y, Estacion M, Schulman BR, Tokuno H, Apkarian AV, Dib-Hajj SD, Waxman SG. Pharmacotherapy for pain in a family with inherited erythromelalgia guided by genomic analysis and functional profiling. JAMA Neurol. 2016 Jun 1:73(6):659-67.

Cao L, McDonnell A, Nitzsche A, Alexandrou A, Saintot PP, Loucif AJ, Brown AR, Young G, Mis M, Randall A, Waxman SG, Stanley P, Kirby S, Tarabar S, Gutteridge A, Butt R, McKernan RM, Whiting P, Ali Z, Bisland J, Stevens EB. Pharmacological reversal of a pain phenotype in iPSC-derived sensory neurons and patients with inherited erythromelalgia. Sci. Transl Med. 2016 Apr 20:8(335).

Tanaka BS, Zhao P, Dib-Hajj FB, Morisset V, Tate S, Waxman SG, Dib-Hajj SD. A gain-of-function mutation in Nav1.6 in a case of trigeminal neuralgia. Mol. Med. 2016 Aug 3;22 EPub.

Han C, Huang J, Waxman SG. Sodium channel Nav1.8: Emerging links to human disease. Neurology. 2016 Feb 2; 86(5): 473-83.

Dib-Hajj SD, Black JA, Waxman SG. NaV1.9: a sodium channel linked to human pain. Nat Rev Neurosci. 2015 Sep; 16(9): 511-9.

Click here for more published work from the Center